Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax delivered good news Nov. 9. It announced its Covid-19 vaccine's been fast-tracked by the FDA.

Novavax Steals Some of Pfizer's Thunder With Fast Track Designation

What is a big deal for the biotech is what happens next with its COVID-19 vaccine candidate.

Novavax Didn't Come Close to Analysts' Q3 Estimates -- and It's No Big Deal

Novavax, Inc. (NVAX) CEO Stan Erck on Q3 2020 Results - Earnings Call Transcript

GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2020.

Novavax Reports Third Quarter 2020 Financial and Operational Results

NVAX stock has promise after Phase 3 data is released, but investors will have to be ready and willing to play the long game. The post Don't Expect Massive Short-Term Gains in Novavax Stock Right Now appeared first on InvestorPlace.

Don't Expect Massive Short-Term Gains in Novavax Stock Right Now

The US Food and Drug Administration has granted “fast track” status to Novavax's experimental coronavirus vaccine, the company announced Monday. The designation will allow the Maryland-based biotech firm to submit its application for regulatory approval piecemeal as data becomes available — rather than waiting to compile all the results before submitting the application.

Novavax COVID vaccine gets ‘fast track' status from FDA

Many traders have been counting on NVAX stock to be the winner of the Covid-19 vaccine race. Their argument just got a lot stronger.

Stick with Novavax as the Vaccine Competition Goes Global

Pfizer

AstraZeneca

BioNTech SE

Johnson & Johnson

Moderna

A safe and effective Covid-19 vaccine is seen by investors and policymakers as a solution to get the global economy back on track.

Coronavirus vaccine frontrunner Pfizer delivers key trial data – here's where the other vaccines stand

Shares in US biotech firm Novavax leapt 7% on Monday after announcing that the US FDA has granted fast-track authorization for its COVID-19 vaccine. The FDA's move would help speed up the development of the vaccine, scientifically called NVX-CoV2373, after Novavax delayed its US trial last month to the end of November.  It was postponed due to delays in ramping up the vaccine's manufacturing process.

Novavax leaps 7% after its COVID-19 vaccine won US FDA fast-track authorization

Novavax, Inc. (NASDAQ: NVAX), which is on the cusp of initiating a late-stage clinical trial of its coronavirus vaccine candidate in the U.S., said Monday that the vaccine candidate has received fast track designation from the FDA. What Happened: Novavax said the FDA has granted fast track designation for NVX-CoV2373, which is a stable, prefusion protein made using Novavax's nanoparticle technology that includes its proprietary MatrixM adjuvant.

Novavax Rallies After FDA Accords Fast Track Designation For Investigational Coronavirus Vaccine

Inovio Pharmaceuticals

Vaxart

These three pre-revenue COVID-19 vaccine stocks took a beating last month.

Why Inovio Pharmaceuticals, Novavax, and Vaxart Crashed in October

Novavax Inc. said Monday it has been granted U.S. Food and Drug Administration fast track designation for its COVID-19 vaccine candidate, a move that should accelerate development of the vaccine. The company is aiming to get the candidate, called NVXCoV2373, into a Phase 3 trial in the U.S. and Mexico by end-November.

Novavax wins FDA fast track designation for COVID-19 vaccine candidate

GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company's COVID-19 vaccine candidate. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax' nanoparticle technology and includes its proprietary MatrixM™ adjuvant.

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

Novavax is attempting to bring a Covid-19 vaccine to market in a new way. This makes NVAX stock a risk with potential rewards.

Novavax May Profit From Life in the Slow Lane

The combination vaccine could save massive amounts of resources.

Here's Why This Laggard in the Coronavirus Vaccine Race Could Still Win

Abbott Labs

These companies are working on drug catalysts that could fuel massive expansion.

3 Coronavirus Stocks With Long-Term Growth Potential

These companies won't cross the finish line first. But if and when they do, they're sure to grab market share.

These 2 Coronavirus Vaccine Stocks Could Be Game-Changers

Our indicative theme of Coronavirus Vaccine stocks – which includes a diverse set of U.S.-based pharma and biotech companies developing Covid vaccines – is up by about 560% year-to-date, on an equally weighted basis, compared to the S&P 500 which has gained just about 4% over the same period.

Moderna, Novavax, Pfizer: How Are Coronavirus Vaccine Stocks Faring?

The company is making moves that signal its growth from the coronavirus vaccine is here to stay.

Is Novavax About to Achieve Warp Speed in the Coronavirus Vaccine Race?

Australia has agreed to purchase another 50 million doses of two more COVID-19 vaccines, Prime Minister Scott Morrison said on Thursday, as Canberra aims to complete a mass inoculation programme within months.

Australia signs two more COVID-19 vaccine deals

Australia joins a growing list of countries that have locked in orders for NVX-CoV2373.

Novavax to Provide 40 Million Doses of Its COVID-19 Vaccine Candidate to Australia

NVAX stock is likely to stay under further pressure until it can release more positive clinical data The post Without Positive Vaccine News, Novavax May Fall Further appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company Daily Picks: Stocks to Buy Ahead of the Election

Without Positive Vaccine News, Novavax May Fall Further

Novavax announced its latest Covid-19 vaccine deal, with Australia, and confirmed that it's on pace to release final-phase clinical trials data by the first quarter of 2021. NVAX stock rose.

Novavax Announces Covid-19 Vaccine Supply Deal With Australia

Heads of Terms signed to acquire 40 million doses of NVX-CoV2373 Heads of Terms signed to acquire 40 million doses of NVX-CoV2373

Novavax and Commonwealth of Australia Announce Agreement in Principle for Acquisition of Novavax COVID-19 Vaccine

But Moderna still has at least one important edge.

News for Novavax Stock (NVAX)